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Renal cysts in autosomal dominant polycystic kidney disease
arise from cells throughout the nephron, but there is an
uncertainty as to whether both the intercalated cells (ICs) and
principal cells (PCs) within the collecting duct give rise to
cysts. To determine this, we crossed mice containing loxP
sites within introns 1 and 4 of the Pkd1 gene with transgenic
mice expressing Cre recombinase under control of the
aquaporin-2 promoter or the B1 subunit of the proton
ATPase promoter, thereby generating PC- or IC-specific
knockout of Pkd1, respectively. Mice, that had Pkd1 deleted
in the PCs, developed progressive cystic kidney disease
evident during the first postnatal week and had an average
lifespan of 8.2 weeks. There was no change in the cellular
cAMP content or membrane aquaporin-2 expression in their
kidneys. Cysts were present in the cortex and outer medulla
but were absent in the papilla. Mice in which PKd1 was
knocked out in the ICs had a very mild cystic phenotype as
late as 13 weeks of age, limited to 1–2 cysts and confined to
the outer rim of the kidney cortex. These mice lived to at
least 1.5 years of age without evidence of early mortality. Our
findings suggest that PCs are more important than ICs for
cyst formation in polycystic kidney disease.
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Renal cysts in autosomal dominant polycystic kidney disease
(ADPKD) arise from cells throughout the nephron. Analysis
of human ADPKD cyst fluid reveals two major cyst types; one
with sodium and chloride hypotonic to plasma (derived
presumably from distal nephron) and the other with sodium
and chloride isotonic to plasma (thought to derive from
proximal nephron).1 Immunohistochemical studies, using
stains for aquaporins, lectins, and other markers have yielded
variable results, but suggest that a substantial percentage of
cysts in ADPKD arise from distal nephron, including the
collecting duct.2–5 Within the collecting duct, there is an
uncertainty as to whether both cell types, namely intercalated
(IC) and principal (PC) cells, give rise to cysts. No studies
have determined the collecting duct cellular pattern of
expression of the proteins responsible for ADPKD, poly-
cystin-1, and -2;6,7 this relates to the lack of antibodies with
adequate sensitivity and specificity. A second key point relates
to primary cilia expression by these cell types. Numerous
studies have implicated the primary cilium as a key factor in
cystogenesis, as mutations of multiple different ciliary
proteins lead to renal cyst formation;5 both polycystin-1
and -2 are associated spatially with the primary cilium.8
Ultra-structural studies done over 45 years ago detected
primary cilia on rat PCs, but not ICs.9 This conclusion was
supported by one subsequent study (in 1989) focused on rat
inner medullary collecting duct (which has very few ICs).10
In contrast, modern technology has shown clearly that in the
mouse, both PCs and ICs contain primary cilia. A recent
report found that mouse ICs have a primary cilium by
staining for acetylated a-tubulin (a marker of the ciliary
axoneme) as well as by scanning electron microscopy.11 Thus,
based on the above considerations, there is no compelling
reason a priori to suspect that ICs are unable to give rise to
cysts in ADPKD.
An animal model of ADPKD would be ideal to evaluate
the roles of IC and PC in cyst formation. Several models of
autosomal recessive polycystic kidney disease exist, including
congenital polycystic kidney (cpk) mice, oak ridge polycystic
kidney (Tg737) mice, and polycystic kidney (pck) rats.12
However, these involve mutations in proteins other than
polycystin-1 and -2. A number of animal models of ADPKD
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exist; however, most of these have proven to be problematic.
Mice with homozygous mutations of the mouse orthologs of
the human genes encoding polycystin-1 and -2 (Pkd1 and
Pkd2) die in utero because of multiple organ involvement,
some of which is not typical for ADPKD.13–17 Heterozygous
Pkd1 and Pkd2 knockout (KO) mice develop limited renal
cysts late in life and have not, therefore, been highly useful for
analysis.13,16 The Pkd2WS25 model is perhaps most similar to
human ADPKD.18 In this spontaneous loss of heterozygosity
model, recombination of the Pkd2WS25 allele leads to renal
cysts if the animal contains a Pkd2 null allele. However, as
PKD1 mutations account for the large majority of cases of
ADPKD, continued efforts have focused on targeting this
allele. These approaches have utilized largely the renal-
specific KO of Pkd1 in mice. One model used mice expressing
the g-glutamyl transpeptidase promoter coupled to Cre
recombinase and loxP-flanked (floxed) Pkd1 exons 2–6.19
These animals developed proximal and distal nephron cysts
and survived about 4 weeks––long enough to examine
potential signaling pathways, but limiting more long-term
analysis. A similar strategy was employed in which, Ksp-Cre
transgenic mice were bred with mice containing floxed exons
2–4 in Pkd1.11 This resulted in Cre expression selectively in
thick ascending limb through the collecting duct; however,
the animals survived only 3 weeks, perhaps because of early
(E11.5) Cre expression. To overcome early lethality, mice
were generated with tamoxifen-inducible Pkd1 deletion using
a Ksp-CreERT2 transgene and floxed Pkd1 exons 2–11.20
When Pkd1 is disrupted at 3–6 months, a mild cystic
phenotype is obtained, but when Pkd1 is disrupted at
4 days of age, severe cyst formation occurs. This latter
model may hold the greatest promise for studying cystogen-
esis in ADPKD; however, it is still not possible, because
of the issues described above, to determine the collecting
duct cell type of origin of the cysts. To address this, this
study employed a Cre/loxP strategy to selectively mutatePkd1
in PC and IC. We report a marked difference in the severity of
cystic kidney disease in these two new mouse models of
ADPKD.
RESULTS
Characterization of principal cell polycystin-1 knockout
(PC-Pkd1 KO) mice
A total of 81 out of 389 pups (20.8%) were PC-Pkd1 KO
(homozygous for the Pkd1cond allele and heterozygous for
the AQP2-Cre transgene). Here, 105 animals (27.0%) were
homozygous for the Pkd1cond allele, but did not have
the AQP2-Cre transgene. Ninety-four animals (24.2%) were
heterozygous for the Pkd1cond allele and contained the AQP2-
Cre transgene. However, 109 animals (28.0%) were hetero-
zygous for the Pkd1cond allele, but did not have the AQP2-Cre
transgene. These genotype frequencies were not significantly
different (P¼ 0.18).
A total of 57 PC-Pkd1 KO animals were kept with
littermates until natural death. The mean survival of the
PC-Pkd1 KO animals was 8.2 weeks (range 2.1–21.6 weeks,
s.e.±0.7) (Figure 1). Five animals, each of the three other
genotypes, were kept alive for comparison and all remained
alive at 78 weeks (1.5 years). Thus, the heterozygous PC-Pkd1
KO mice had a normal life span.
At birth, there were no macroscopic or microscopic renal
cysts. Bilateral renal cysts were grossly apparent in all the
PC-Pkd1 KO mice at week 1, with progressive cyst formation
and enlargement through week 4 (Figure 2a–d and 3a).
Total cysts per kidney exceeded 100 starting on week 1
(Figure 4). Cysts were most apparent in the cortex and outer
medulla, whereas cysts were not observed in the papilla. Real-
time PCR for polycystin-1 mRNA in the papillary collecting
duct, from wild-type mice, showed this region contains 1.46
times the amount of polycystin-1 mRNA (normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) as
compared with outer medulla. Hence, the absence of
papillary cysts is not because of the failure of papillary CD
to express polycystin-1 mRNA. No cysts were apparent
macroscopically or microscopically in any control animals
killed at any time point from week 1 through 39 weeks of age.
No gross abnormalities were present in non-renal organs in
the PC-Pkd1 KO mice.
Staining for Dolichos biflorus agglutinin confirmed that
cysts are of the collecting duct origin (Figure 5a and b). AQP2
expression of cystic epithelium was variable––some cysts
displayed circumferential staining, some with no staining,
and others with partial staining (images not shown). The
presence of renal cysts at week 1 and thereafter was associated
with a higher kidney weight (Figure 6a). Body weight was less
than control animals at 4 weeks and thereafter (Figure 6b).
Renal insufficiency was evident as early as week 2: blood urea
nitrogen (BUN) in PC-Pkd1 KO was 41.2 mg/dl (n¼ 4,
s.e.±8.4) versus 19.2 mg/dl (n¼ 5, s.e.±1.2) in control
animals (P¼ 0.0224). Severe renal insufficiency was evident
at 4 and 8 weeks of age (Figure 6c).
In order to determine whether there were alterations in
cyclic AMP (cAMP) levels or expression of the target protein,
AQP2, total kidney cAMP content, and membrane-associated
AQP2 protein levels were ascertained. There was no
difference in cAMP content between the 4-week-old
PC-Pkd1 KO mice (105.1±14.9 pmol cAMP/mg total cell
protein, n¼ 5) and controls (125.0±17.1 pmol cAMP/mg
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Figure 1 | The mean survival of 57 principal cell polycystin-1
knockout (PC-Pkd1 KO) mice was 8.2 weeks (range 2.1–21.6,
s.e.±0.7).
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total cell protein, n¼ 5). Similarly, there were no differences
in glycosylated or unglycosylated AQP2 levels between the
PC-Pkd1 KO and the control mice (Figure 7).
Characterization of intercalated cell polycystin-1 knockout
(IC-Pkd1 KO) mice
A total of 26 out of 86 mice (30.2%) were IC-Pkd1 KO:
homozygous for the Pkd1cond allele and contained the B1-Cre
transgene. Seventeen animals (19.8%) were homozygous for
the Pkd1cond allele, but did not have the B1-Cre transgene.
Twenty animals (23.3%) were heterozygous for the Pkd1cond
allele and contained the B1-Cre transgene. However, 23
animals (26.7%) were heterozygous for the Pkd1cond allele,
but did not have the B1-Cre transgene. These genotype
frequencies were not significantly different (P¼ 0.55).
In comparison with PC-Pkd1 KO, IC-Pkd1 KO animals
had a very mild cystic phenotype (Figure 2e–g, 3 and 4). Two
of the five IC-Pkd1 KO animals killed after 4 weeks had no
cysts macroscopically or microscopically. One animal had
one macroscopic cyst in one kidney. Another animal had two
macroscopic cysts in one kidney and three in the other. The
fifth had one macroscopic cyst in one kidney and an
additional microscopic cyst in the contralateral kidney. All
cysts at 4 weeks of age were limited to the cortex.
At 8–9 weeks of age, one of the five IC-Pkd1 KO mice had
no renal cysts. The remaining four had 1–2 macroscopically
apparent cysts in each kidney. As in the 4-week-old animals,
cysts were limited to the cortex. At 17 weeks, all the five
animals had cysts in both kidneys (Figure 3 and 4). These
averaged two cysts per kidney. Most cysts in animals at this
age were relatively small (as compared with cysts in the PC-
Pkd1 KO mice). ICs represent about 30% of cortical and
outer medullary collecting duct cells (Figure 8); hence, the
extremely low number of cysts in the IC-Pkd1 KO mice, as
compared with the PC-Pkd1 KO mice, is not because of the
number of ICs.
Body weight and kidney weight were not different
between IC-Pkd1 KO and littermate controls, and were not
different than PC-Pkd1 controls (Figure 6a and b). BUN
Figure 3 | Representative magnetic resonance imaging of
kidneys obtained from (a) principal cell polycystin-1 knockout
(PC)-Pkd1 KO and (b) intercalated cell polycystin-1 knockout
(IC-Pkd1 KO). The magnetic resonance imaging is from PC-Pkd1
KO mice at 2 weeks of age and IC-Pkd1 KO mice at 13 weeks
of age.
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Figure 4 | Number of cysts at varying ages in the principal cell
polycystin-1 knockout (PC-Pkd1 KO) and the intercalated cell
polycystin-1 knockout (IC-Pkd1 KO) mice. PC-Pkd1 KO bars are
at maximal height––these kidneys had 4100 cysts. N¼ 10 kidneys
each data point.
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Figure 2 | Representative sections of the principal cell
polycystin-1 knockout (PC-Pkd1 KO) mice (a–d) and the
intercalated cell polycystin-1 knockout (IC-Pkd1 KO) mice
(e–g) stained with hematoxylin and eosin. (a) PC-Pkd1 KO at
birth,  4. (b) PC-Pkd1 KO at 1 week,  2. (c) PC-Pkd1 KO at 2
weeks,  2. (d) PC-Pkd1 KO at 4 weeks,  2. (e) IC-Pkd1 KO at 4
weeks. (f) IC-Pkd1 KO at 8 weeks. (g) IC-Pkd1 KO at 13 weeks.
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at 4 weeks was higher in IC-Pkd1 KO than in littermate
controls, but not likely meaningful as the BUN at 17 weeks
was similar. (Figure 6c). BUN in IC-Pkd1 KO was not
different from the BUN in PC-Pkd1 controls (Figure 6c). No
abnormalities were grossly apparent in any non-renal organs
in the IC-Pkd1 KO animals, and no cysts were observed in
any control animal through 39 weeks of age. None of the IC-
Pkd1 KO animals died during 78 weeks (1.5 years) of follow-
up (N¼ 10).
DISCUSSION
In this study, two new mouse models of ADPKD were
created. The PC-Pkd1 KO mice were generated using the
AQP2-Cre mice which express Cre selectively in renal PCs
and in the male reproductive tract.21–24 The PC-Pkd1 KO
mice have a severe, yet viable, kidney-limited cystic
phenotype. Animals develop cysts at 1 week of age, renal
insufficiency at 2 weeks, and progressive kidney enlargement
and cyst growth. These mice have an average life span of 8.2
weeks with a wide range in survival. Thus, PC polycystin-1
dysfunction can, in of itself, cause a profound renal cystic
disease.
The IC-Pkd1 KO model was generated using the B1-Cre
mice which express Cre selectively in ICs within the kidney;
these mice have low-level Cre expression in the brain,
intestine, and uterus.25 The IC-Pkd1 KO mice had very few
cysts with minimal to no impairment in renal function. Cysts
in the IC-Pkd1 KO mice were confined largely to the cortex,
and particularly near the capsule. This very mild phenotype
and renal cyst localization is not because of an incomplete IC
Cre expression; B1-Cre mice confer virtually 100%
IC-specific target gene recombination throughout the cortex
and outer medulla as evidenced by crossing B1-Cre mice with
ROSA26-YFP (yellow fluorescent protein) reporter animals.25
Furthermore, we found that IC constitute 30% of the
collecting duct cell types in the cortex and 28% in the outer
medulla (another study found that IC make up 40% of the
cortical and outer medullary collecting duct cells26); hence,
the low number of cysts and their absence in outer medulla is
not because of the limited numbers of IC. As it is currently
not possible to localize polycystin-1 protein or mRNA to
specific collecting duct cell types, the reasons for the limited
number of cysts and the failure to form outer medullary cysts
are speculative. Mouse IC contain a primary cilium;11 hence,
failure to form cysts is not because of the lack of this
structure. It may be that IC lacks expression of, and/or
functionally important, polycystin-1. In this regard, it is
possible that cysts in the IC-Pkd1 KO mice arise solely from
the connecting segment. B1-Cre-mediated recombination
(using the ROSA26-YFP reporter mice) occurs in the
connecting segment cells that co-express AQP2;25 hence, it
is conceivable that these ‘hybrid’ cells, which have features of
both IC and PC, express the V-ATPase characteristic of ICs as
well as the functionally important polycystin-1. Confirma-
tion of this is problematic as there is no way to specifically
target the connecting segment. Furthermore, segmental
nephron markers are lost largely in cystic epithelium and
do not identify accurately the cell type of origin.27 Thus,
although the current data suggest that the collecting duct and
the connecting segment cysts in ADPKD arise only from cells
with PC characteristics, confirmation is required.
The PC-Pkd1 KO mice do not express cysts in the renal
papilla, yet mouse papillary collecting ducts possess a
primary cilia11 and polycystin-1 mRNA levels that exceed
those in the outer medulla. Failure to express Cre
recombinase in the papillary collecting duct is not the reason
Figure 5 | Representative sections of the principal cell
polycystin-1 knockout (PC-Pkd1 KO) (a–b) and the
intercalated cell polycystin-1 knockout (IC-Pkd1 KO) mice (c)
stained with Dolichos biflorus agglutinin (brown) showing the
collecting duct origin of cysts. (a) PC-Pkd1 KO at week 4,  2.
(b) PC-Pkd1 KO at week 4,  20. (c) IC-Pkd1 KO at week 13,  20.
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for cyst absence, as AQP2-Cre mice express active Cre in
virtually every PC in this nephron segment.21–24,28 In
contrast, in the Ksp-Cre Pkd1 model, tubule ectasia is
apparent in the renal papilla.11 The reason for the different
papillary phenotypes is uncertain, but may relate to
differences in the timing of Cre expression: Cre is active
much earlier in renal development in the Ksp-Cre Pkd1 mice
(E11.5) as compared with the PC-Pkd1 KO mice (E18.5).
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Figure 6 | Kidney weight, body weight and BUN in principal (PC) and intercalated cell (IC) polycystin-1 (Pkd1) knockout mice.
(a) Kidney weight of the principal cell polycystin-1 knockout (PC-Pkd1 KO) and the intercalated cell polycystin-1 knockout (IC-Pkd1 KO)
expressed as mean and s.e. *Po0.0001 for the comparison of PC-Pkd1 KO and PC controls at weeks 1, 2, 4, and 8. ^P¼ 0.0001 at 4 weeks
and #P¼ 0.0026 at 8 weeks for the comparison of PC-Pkd1 KO and IC-Pkd1 KO. Kidney weight comparison of IC-Pkd1 KO and IC controls was
NS. (b) Body weight of PC-Pkd1 KO and IC-Pkd1 KO expressed as mean and s.e. *Po0.0001 for the comparison of PC-Pkd1 KO and PC
controls at 4, 8, and 13 weeks. Body weight comparison was NS at D7 and D14. ^P¼ 0.024 at 4 weeks and #P¼ 0.0026 at 8 weeks for the
comparison of PC-Pkd1 KO and IC-Pkd1 KO. Body weight comparison IC-Pkd1 KO and IC controls was NS. (c) Blood urea nitrogen (BUN) of
PC-Pkd1 KO and IC-Pkd1 KO expressed as mean and s.e. *Po0.0001 for the comparisons of PC-Pkd1 KO versus PC controls and PC-Pkd1 KO
versus IC-Pkd1 KO at 4 and 13 weeks. #P¼ 0.0054 for the comparison of IC-Pkd1 KO and IC controls at 4 weeks. The difference between
IC-Pkd1 KO and IC controls at 13 weeks was NS.
Control PC Pkd1 KO
AQP2-glycosylated 
AQP2
β-actin
Figure 7 | Western blot of glycosylated and unglycosylated
AQP2 levels in 4-week-old principal cell polycystin-1
knockout (PC-Pkd1 KO) and control mice. Data are shown from
four mice in each group.
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Figure 8 | Number of intercalated cells (ICs) in the mouse
collecting duct. Sections of control mouse kidneys were
immunostained for the V-ATPase B1 subunit (B1), and the percent
of B1 positive cells (compared with total collecting duct cells) in a
given region of kidney determined. The percent of ICs within the
collecting duct was also assessed by breeding B1-Cre mice with
reporter mice transgenic for ROSA26-YFP; YFP-positive ICs were
yellow. Each data point represents counting of 10 sections per
kidney in 5 kidneys. CCD, cortical collecting duct; OMCD, outer
medullary collecting duct; IMCD, inner medullary collecting duct.
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The mechanisms responsible for massive cyst formation in
the PC-Pkd1 KO mice remain conjectural. Although
cystogenesis is associated strongly with defective cilia, there
is no evidence to suggest that deficiency of polycystin-1 in
PCs leads to structural abnormalities in cilia. Studies in Pkd1
KO endothelial cells,29 epithelial cells lining kidney cysts from
patients with ADPKD30–32, and in Caenorhabditis elegans with
disruption of a Pkd1 homolog33 all indicate that primary cilia
are present and are grossly intact. More specifically, collecting
duct cells from mice with Pkd1 disruption have grossly intact
primary cilia.11,34 In addition, these studies found no
evidence that AQP2 levels or cellular cAMP content were
altered in the PC Pkd1 KO mice. These observations are of
interest in that vasopressin can directly regulate cyst growth
in a model of ADPKD,35 cAMP stimulates human PKD
epithelial cell growth and fluid secretion,36 and V2 receptor
antagonism reduces cystic disease in animal models.37
Further, renal cAMP levels have been reported to be elevated
in PKD.38 In contrast, our findings suggest that an overall
increase in renal cAMP content or downstream vasopressin
and cAMP targets (AQP2) do not occur invariably, at least
insofar as PC-derived cysts are concerned. A wide variety of
other signaling pathways have been invoked in cystogenesis39
—exploration of these possibilities, some of which may be of
greater importance in PCs, would be of substantial interest.
Finally, our studies do not preclude the possibility that V2
receptor activation and cAMP are important––such conclu-
sions could only be assessed by examining the effect of V2
antagonism in this model.
There are both limitations and advantages of the PC-Pkd1
KO mouse model. The ‘two-hit’ hypothesis proposes that a
mutation of the normal PKD1 allele, or a somatic modifier
gene, occurs before the development of renal cysts. In the PC-
Pkd1 KO model, animals are born with two mutant Pkd1
alleles. Another potential limitation is that in human
ADPKD, cysts develop from all nephron segments, whereas
cysts arise only from the collecting duct in the PC-Pkd1 KO
model. Third, in the PC-Pkd1 KO mouse, cysts develop
shortly after birth; this necessitates administration of agents
to the mother, and adequate secretion into breast milk, in
order to examine the effect of early drug intervention in
disease progression. Despite these limitations, the PC-Pkd1
KO model permits analysis of the pathophysiology of
progressive cyst formation and associated renal insufficiency,
as well as evaluation of the effect of therapeutic intervention.
Another potential benefit is the mean lifespan of 8.2 weeks;
this facilitates obtaining mortality data in a reasonably short
time. Hence, on balance, the PC-Pkd1 KO model should
prove useful for the further study of ADPKD and drug
intervention.
In conclusion, two viable, kidney-specific mouse models
of ADPKD were created. PCs are the major cell type leading
to cyst formation in the CD; although, the paucity of cyst
formation in the IC-Pkd1 KO mice suggests that this cell type
does not play a significant role in the pathogenesis of renal
cyst formation. The lack of cyst formation in IC-Pkd1 KO is
of particular interest in that these cells express cilia––it
remains to be determined whether they express polycystin-1.
The lack of papillary cyst formation suggests a strong
temporal relationship between the timing of polycystin-1
disruption and cyst development. Finally, the PC-Pkd1 KO
model is a viable model that should be useful for the further
study of ADPKD and for testing therapeutic interventions.
METHODS
Generation of PC-Pkd1 KO mice
The PC-specific KO mice were generated in a manner similar to that
described earlier.21–23,40 Floxed Pkd1 mice (Pkd1cond) have loxP sites
flanking exons 1 and 4 of the Pkd1 gene, permitting selective
deletion of essential coding regions on exposure to Cre recombi-
nase.41 Mice were bred to obtain homozygotes for the Pkd1cond
allele; these were bred with AQP2-Cre mice with PC-specific
expression of Cre recombinase. AQP2-Cre mice contain a transgene
with 11 kb of the mouse AQP2 gene 50 flanking region driving
expression of Cre recombinase. The AQP2-Cre mice are identical to
those fully characterized in earlier publications by our group,21–23
and as used in collaboration with other investigators.40,42 Female
AQP2-Cre mice were mated with male Pkd1cond mice; female
offspring heterozygous for both AQP2-Cre and floxed Pkd1cond were
bred with males homozygous for Pkd1cond Animals homozygous for
Pkd1cond and heterozygous for AQP2-Cre (PC-Pkd1 KO) were used.
Males containing the AQP2-Cre transgene were not used because
AQP2 is expressed in sperm and causes recombination in fertilized
oocytes. Offspring of the other possible genotypes that did not have
Cre-mediated recombination served as the comparison group for
the PC-Pkd1 KO animals.
Generation of IC-Pkd1 KO mice
The IC-specific KO mice were generated using the Pkd1cond mice
described above. Homozygous Pkd1cond mice were bred with B1-Cre
mice with Cre recombinase expressed in IC.25 B1-Cre mice contain a
transgene with 7 kb of the mouse V-ATPase B1 subunit promoter
driving Cre recombinase and an SV40 polyA tail; the B1-Cre mice
have been characterized extensively and confer complete IC-specific
KO (all ICs undergo recombination) of the target gene as assessed
using ROSA26-YFP reporter mice.25 Breeding strategy to obtain the
IC-Pkd1 KO mice and controls was as described above.
Genotyping
Tail genomic DNA was PCR amplified for the AQP2-Cre transgene
and the B1-Cre transgene using oligonucleotide primers that
amplify a region within Cre: CreF (50-CAT TAC CGG TCG ATG
CAA CGA G-30) and CreR (50- TGC CCC TGT TTC ACT ATC CAG
G-30). DNA was PCR amplified for the Pkd1cond and Pkd1wt alleles
using primers GerF2 (50- GGC TAT AGG ACA GGG ATG ACA T-30)
and GerR6 (50- CAT ATT CCT CAC CTG GGA ACA G-30). The
amplified product of the Pkd1cond allele is 34 base pairs longer than
the wild-type allele, corresponding to the loxP site in intron 4.
Survival and BUN
The PC-Pkd1 and IC-Pkd1 KO mice and littermate controls were
allowed to survive to determine lifespan. Blood was collected from
animals by cardiac puncture or from tail biopsy. Serum urea
concentration was measured (BioAssay Systems, Hayward, CA,
USA) and the BUN, expressed in mg/dl, was calculated by dividing
the urea by 2.14.
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Real-time PCR for polycystin-1 mRNA in papilla and outer
medulla
Papilla and outer medulla were dissected from wild-type mouse
kidney. Inner medullary collecting ducts were isolated from papilla
as described earlier.43 RNA was isolated using the Chomczynski
method44 and reverse transcribed to cDNA using SuperScript II
(Invitrogen, Carlsbad, CA, USA). Pkd1 was amplified using Pkd1 F1
(5-CGC CAG TGG TCT GTT TTT G–30) and Pkd1 R1 (50-ACG
GGC CAT GTT GTA GAG AG–30) intron spanning primers on a
Smart Cycler System (Cepheid, Sunnyvale, CA, USA).
Histology
The PC-Pkd1 KO and IC-Pkd1 KO mice and littermate controls
were killed at varying ages. For histology, kidneys were fixed in 10%
normal-buffered formalin, embedded in paraffin, and sectioned
sagitally to obtain all layers of the kidney in a single section. Sections
were stained with hematoxylin and eosin.
Immunohistochemistry
To show the collecting duct origin of cysts in the PC-Pkd1 KO
animals, frozen sections were blocked with streptavidin–biotin
blocking kit, incubated with biotinylated D. biflorus agglutinin
followed by horseradish peroxidase streptavidin, developed using
3,30-diaminobenzidine, and counterstained with hematoxylin (all
reagents from Vector Laboratories, Burlingame, CA, USA).
Immunofluorescence
To determine the pattern of AQP2 expression in cysts, deparaffi-
nized sections were incubated with anti-AQP2 goat polyclonal IgG
(Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA) followed
by Alexa Fluor 555 donkey anti-goat IgG (Invitrogen, Carlsbad, CA,
USA). To determine the distribution and number of ICs in the
collecting duct, deparaffinized sections were incubated with a
polyclonal rabbit antiserum to the V-ATPase B1 subunit,45 followed
by goat anti-rabbit IgG conjugated to CY3. The number and
distribution of ICs were further determined by breeding B1-Cre
mice with reporter mice transgenic for ROSA26 promoter-loxP-
stop-loxP-YFP.25 The loxP sequences undergo recombination in the
presence of Cre, excising the stop sequence, and permitting YFP
expression. Hence, cells which are yellow represent cells that express
the B1 promoter. In both the V-ATPase B1 subunit staining and the
B1-Cre-mediated YFP expression, the collecting ducts are identified
readily. Total collecting duct cells and the number immunostained
or yellow cells were counted (10 sections per kidney in 5 kidneys).
Western blotting for AQP2
Mouse kidneys were homogenized in 300 mM sucrose, 10 mM
triethanolamine, 1 mM EDTA, and Roche complete protease
inhibitors (pH 7.2). The samples were spun at 4000 g for 10 min
at 41C, the supernatant centrifuged for 50 min at 17,000 g at 41C,
and the final pellet resuspended in homogenization buffer. Protein
concentration was determined using the BCA protein determination
kit. Samples were run on a denaturing NUPAGE 4–12% Bis Tris
mini gel, proteins transferred to a nylon membrane, the membrane
incubated with the rabbit AQP2 primary antibody used in
immunofluorescence studies, incubated with a horseradish perox-
idase-conjugated goat anti-rabbit secondary antibody, and visua-
lized using an enhanced chemiluminescence detection system. The
membrane was stripped and re-probed using a rabbit b-actin
antibody for loading normalization.
Cyclic AMP (cAMP) assay
Mouse kidneys were snap frozen and ground to a fine powder in
liquid nitrogen, then homogenized in cold 5% tricarboxylic acid. An
aliquot was removed for protein determination and the remainder
was centrifuged at 600 g for 10 min at 41C. The supernatant was
extracted with three volumes of water-saturated ether, the aqueous
extract dried, reconstituted in cAMP assay buffer, and assayed
directly in a cAMP enzyme immunoassay using the manufacturer’s
protocol (Assay Design, Ann Arbor, MI, USA).
Magnetic resonance images
High-resolution magnetic resonance imaging was obtained from
ex vivo whole kidney on a 7.0. T scanner (BioSpec 70/30, Bruker
BioSpin Co., Billerica, MA, USA) using a 7.0 cm-diameter volume
transmit and 1.0 cm-diameter surface receive radio frequency coils.
For each specimen, two sets of 3D images (256 128 128 matrix
size at 100 mm isotropic spatial resolution) were obtained using
standard rapid acquisition with relaxation enhancement sequence,
including a fluid-attenuated inversion-recovery (600 ms inversion
time, 800 ms time-to-repetition, 7.3 ms effective time-to-echo, and
echo-train-length of 4) image, and a proton-density (2000 ms time-
to-repetition, 7.3 ms time-to-echo, and echo-train-length of 8)
image. The total scan time for the images was B2 h.
Statistics
Data on genotype were compared by the chi-squared test. Comparisons
between KOs and their respective controls for BUN, kidney weight, and
body weight were done by one-way analysis of variance with the
Bonferroni correction. Comparisons between PC-Pkd1 KO and controls
for cAMP and AQP2 levels were done by the Student’s t-test. Po0.05
was taken as significant. Data are expressed as mean±s.e. of the mean.
Animal use
All animal experiments were approved ethically by the University of
Utah Institutional Animal Care and Use Committee.
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